Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA
1. DexCom sold an FDA-cited 'adulterated' glucose monitoring device. 2. G7 device inaccuracies have led to patient complaints and competitive losses. 3. Financial scrutiny over accounting tactics has analysts predicting stock declines. 4. Executives, including CEO, have departed amid worsening public perception. 5. Complaints grew significantly after unauthorized design changes to the G7 device.